ArriVent BioPharma, Inc. Common Stock (AVBP) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Newtown Square, United States. The current CEO is Zhengbin Yao.
AVBP has IPO date of 2024-01-26, 52 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $1.22B.
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
